Kimberley S. Mak, MD, MPH
Associate Professor, Radiation Oncology
Biography
Kimberley S. Mak, MD, MPH, is an Associate Professor of Radiation Oncology at the Chobanian and Avedisian School of Medicine and its affiliate Boston Medical Center (BMC). She received her MPH from Harvard School of Public Health, MD from Harvard Medical School, and AB summa cum laude in Biochemical Sciences from Harvard College. Dr. Mak completed an internship in Internal Medicine at Brigham and Women’s Hospital, followed by residency in the Harvard Radiation Oncology Program, training at Massachusetts General Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Children’s Hospital of Boston, and BMC. Dr. Mak has board certification in Radiation Oncology by the American Board of Radiology.
Dr. Mak’s specialties include thoracic, gastrointestinal, breast, and musculoskeletal malignancies. She leads the Cyberknife® radiosurgery program for thoracic and gastrointestinal malignancies. She speaks English and Cantonese. As Clinical Director of the Department of Radiation Oncology at BMC, she spearheaded quality improvement efforts leading to BMC becoming the first site in Massachusetts to achieve accreditation through the American Society for Radiation Oncology (ASTRO) Accreditation Program for Excellence (APEx). She further analyzes quality metrics as Cancer Liaison Physician for the BMC Cancer Care Committee/American College of Surgeons Commission on Cancer.
Dr. Mak’s research interests include patient-reported outcomes including quality of life and treatment toxicities; disparity outcomes research; intensity-modulated and image-guided radiotherapy; CyberKnife® stereotactic radiotherapy; translational research; and functional imaging in radiotherapy. She has training and experience in biostatistics, epidemiology, decision analysis, meta-analysis, clinical trial design, and molecular and cell biology laboratory work. Dr. Mak serves on multiple committees for ASTRO and the international cooperative research group, NRG Oncology. She has contributed her expertise in working groups for the National Quality Forum, Lung Cancer 360 and International Consortium for Health Outcomes Measurement.
Other Positions
- Member, BU-BMC Cancer Center, Boston University
- Boston Medical Center
- VA Boston Healthcare System
Websites
Education
- Harvard Medical School, MD
- Harvard School of Public Health, MPH
- Harvard College, AB
Publications
- Published on 3/10/2025
Radwan A, Jani CT, Al Omari O, Patel M, Burns L, Mackay Z, Li L, Mahdaviani K, Davidson A, Weinberg J, Everett PC, Suzuki K, Mak KS, Kulke MH, Tapan U. The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients. Oncologist. 2025 Mar 10; 30(3). PMID: 39603266.
Read at: PubMed - Published on 9/6/2024
Lin Y, Qureshi MM, Batra S, Truong MT, Mak KS. Consecutive Daily Versus Every Other Day Stereotactic Body Radiation Therapy Scheduling for Stage I Non-small Cell Lung Cancer. Adv Radiat Oncol. 2024 Dec; 9(12):101625. PMID: 39524524.
Read at: PubMed - Published on 2/1/2024
Mak KS, Scannell Bryan M, Dignam JJ, Shipley WU, Lin Y, Peters CA, Gore EM, Rosenthal SA, Zeitzer KL, D'Souza DP, Horwitz EM, Pisansky TM, Maier JM, Chafe SM, Robin TP, Roach M, Tran PT, Souhami L, Michalski JM, Hartford AC, Feng FY, Sandler HM, Efstathiou JA. Cardiovascular Mortality and Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-term Update of NRG/RTOG 9202. Eur Urol Focus. 2024 Mar; 10(2):271-278. PMID: 38307806.
Read at: PubMed - Published on 12/12/2023
Dudipala H, Burns L, Jani CT, Radwan A, Al Omari O, Patel M, Kilic S, Zhao J, Mak K, Suzuki K, Tapan U. Disparities in Lung Cancer Clinical Trial Discussion and Enrollment at a Safety Net Hospital. Community Health Equity Res Policy. 2023 Dec 12; 2752535X231221394. PMID: 38087807.
Read at: PubMed - Published on 6/8/2023
Qureshi MM, Lin Y, Moeller AR, Yan SX, Dyer MA, Suzuki K, Everett P, Litle V, Truong MT, Mak KS. Change in stage after neoadjuvant chemoradiation is associated with survival in patients with esophageal cancer. J Surg Oncol. 2023 Oct; 128(5):781-789. PMID: 37288789.
Read at: PubMed - Published on 2/23/2023
Jiao XD, Qin BD, Wang Z, Liu K, Wu Y, Ling Y, Qin WX, Wang MM, Yuan LY, Barreto SG, Kim AW, Mak K, Li H, Xu YY, Qiu XM, Wu M, Jin M, Xu LC, Zhong Y, Yang H, Chen XQ, Zeng Y, Shi J, Zhu WY, Ding QQ, Jia W, Liu SF, Zhou JJ, Shen H, Yao SH, Guo ZJ, Li T, Zhou PJ, Dong XW, Lu WF, Coleman RL, Akce M, Akladios C, Puccetti F, Zang YS. Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway). Front Oncol. 2023; 13:860711. PMID: 36910668.
Read at: PubMed - Published on 2/10/2023
Qureshi MM, Kam A, Suzuki K, Litle V, Tapan U, Balasubramaniyan R, Dyer MA, Truong MT, Mak KS. Association between hospital safety-net burden and receipt of trimodality therapy and survival for patients with esophageal cancer. Surgery. 2023 May; 173(5):1153-1161. PMID: 36774317.
Read at: PubMed - Published on 2/8/2023
Oladeru OT, Lam CM, Qureshi MM, Hirsch AE, Mak KS, Dyer MA, Truong MT. Inequalities in Cancer Stage at Diagnosis Among Incarcerated Individuals Undergoing Radiation Therapy at a Large Safety-Net Hospital. Int J Radiat Oncol Biol Phys. 2023 May 01; 116(1):194-198. PMID: 36758643.
Read at: PubMed - Published on 12/28/2022
Asokan S, Pavesi F, Bains A, Qureshi MM, Shetty S, Singh S, Mak KS, Litle VR, Suzuki K. Frailty Index is Associated with Treatment Decisions for Stage I Non-Small Cell Lung Cancer at a High-Burden Safety-Net Hospital. Clin Lung Cancer. 2023 Mar; 24(2):153-164. PMID: 36641324.
Read at: PubMed - Published on 12/25/2022
Siddiqi N, Pan G, Liu A, Lin Y, Jenkins K, Zhao J, Mak K, Tapan U, Suzuki K. Timeliness of Lung Cancer Care From the Point of Suspicious Image at an Urban Safety Net Hospital. Clin Lung Cancer. 2023 Mar; 24(2):e87-e93. PMID: 36642641.
Read at: PubMed
View 37 more publications: View full profile at BUMC